Vitamin A deficiency

Global Vitamin A Market Analysis, Size, Trends and Forecasts to 2029 - A US$745.84 Million Market by 2029, with Expected CAGR of 5.26% Over 2024-2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Fitness & Nutrition, Health, Element, Meat, Urbanization, Growth, Vitamin A, Prevalence, Poultry, Application, Dietary supplement, Livestock, Eye, Skin, Nature, Aquaculture, Safety, Cosmetics, Vitamin A deficiency, Ageing

The global vitamin A market value stood at US$548.36 million in 2023 and is expected to reach US$745.84 million by 2029.

Key Points: 
  • The global vitamin A market value stood at US$548.36 million in 2023 and is expected to reach US$745.84 million by 2029.
  • The market is expected to grow at a CAGR of 5.26% over the projected period of 2024-2029.
  • The rising demand for functional foods, fortified with essential nutrients including vitamin A, has also contributed to market growth.
  • Overall, Asia Pacific's dynamic market landscape positions it as a key player in the global vitamin A sector.

Particles for Humanity Completes Study Confirming No Major Difference in Taste or Smell of Bouillon and Broth with PFH-VAP

Retrieved on: 
Tuesday, April 2, 2024
Consumer, Taste, Vitamin, Humanity, Bill, Humidity, Smell, Vitamin A, Mineral, Multimedia, Vitamin A deficiency, Mulago Foundation, Dietary supplement

CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Particles for Humanity has completed a study showing no major difference between the taste and smell of bouillon cubes containing the company's lead product, a stable form of vitamin A, called PFH-VAP.

Key Points: 
  • CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Particles for Humanity has completed a study showing no major difference between the taste and smell of bouillon cubes containing the company's lead product, a stable form of vitamin A, called PFH-VAP.
  • One reason that food fortification is effective at addressing micronutrient deficiencies is because it does not require consumer behavior change.
  • The inclusion of PFH-VAP did not cause any major differences in taste or smell for cubes stored at either mild or harsh conditions.
  • Particles for Humanity transforms early-stage medical technology into products for people living in low and lower-middle income countries.

Particles for Humanity Establishes Global Advisory Board in Fight Against Vitamin A Deficiency

Retrieved on: 
Tuesday, January 23, 2024
Research, Corporation, University, GAIN, Entrepreneurship, MFR, Mulago Foundation, Poverty, United, Nutrition (journal), Assistant, Learning, Vitamin A, Humanity, Country, Corporate governance, GAVI, Partner, Cadbury Nigeria Plc, Organization, Food fortification, Education, Vitamin A deficiency, UNICEF, Head, Nutrition International (organization), Parthian Partners Limited, Finance, Federal republic, Multimedia, Global health, Bill, Advisory, ACA, Malnutrition, Pregnancy, Advisory board, United Nations, Government, Global Alliance, Management

The four-person advisory board brings significant experience in the fields of malnutrition, food fortification, global health, entrepreneurship, and African markets, which will strengthen the company's strategic plans.

Key Points: 
  • The four-person advisory board brings significant experience in the fields of malnutrition, food fortification, global health, entrepreneurship, and African markets, which will strengthen the company's strategic plans.
  • Members of the Advisory Board bring a diverse skill set from long careers working throughout Africa, Asia, and more.
  • Advisory Board members include:
    Kul Chandra Gautam is the former Deputy Executive Director of UNICEF and Assistant Secretary-General of the United Nations.
  • "It is a privilege to welcome these brilliant individuals onto the Particles for Humanity Advisory Board.

Orsini selected as the exclusive specialty pharmacy for WAINUATM (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy

Retrieved on: 
Thursday, January 4, 2024
Vitamin A deficiency, ELK, AstraZeneca, IDN, FDA, Disease, Ionis, Orsini, Serum, Polyneuropathy, Internationalized domain name, Vitamin A, Pharmacy, Patient, Diagnosis, Disability studies, Amyloidosis

ELK GROVE VILLAGE, Ill., Jan. 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy ("Orsini") has been selected by AstraZeneca and Ionis as the exclusive specialty pharmacy partner for WAINUA™ (eplontersen), an FDA-approved treatment for adults living with hereditary transthyretin-mediated amyloid polyneuropathy (commonly referred to as hATTR-PN or ATTRv-PN).

Key Points: 
  • ELK GROVE VILLAGE, Ill., Jan. 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy ("Orsini") has been selected by AstraZeneca and Ionis as the exclusive specialty pharmacy partner for WAINUA™ (eplontersen), an FDA-approved treatment for adults living with hereditary transthyretin-mediated amyloid polyneuropathy (commonly referred to as hATTR-PN or ATTRv-PN).
  • "Orsini is proud to be the exclusive specialty pharmacy offering access to WAINUA as a new treatment option for patients living with ATTRv-PN," Orsini CEO Brandon Tom said.
  • Indication: WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
  • Note: While Orsini is the exclusive specialty pharmacy partner for WAINUA, it may also be available for use by integrated delivery networks (IDNs) within qualifying IDN-owned specialty pharmacies.

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

Retrieved on: 
Friday, December 22, 2023
Research, FDA, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Quality of life, Tissue, Heart, Heredity, Serum, Polyneuropathy, Death, Inotersen, Ageing, TTR, JAMA, Vitamin A, Diagnosis, Metabolism, Amyloidosis, Pancreas, Disease, Safety, Journal, Heart failure, Disability studies, Sympathetic nervous system, Vitamin A deficiency, Food, Biopharmaceutical, AstraZeneca, Caregiver, ATTR, Patient, Medicine, LICA, Ionis, American Medical Association, Growth, Central nervous system, Pharmaceutical industry

It is also a pivotal moment for Ionis as WAINUA will be the first in a steady cadence of potential commercial launches for the company.

Key Points: 
  • It is also a pivotal moment for Ionis as WAINUA will be the first in a steady cadence of potential commercial launches for the company.
  • Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels.
  • Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.
  • Please see link to US Full Prescribing Information for WAINUA.

Particles for Humanity Receives Approval to Begin a Study of PFH-VAP in Humans

Retrieved on: 
Tuesday, December 12, 2023
Vitamin A, Institutional review board, Research, IRB, Mineral, Mulago Foundation, Pregnancy, Principal investigator, University of Wisconsin–Madison, Bill, Multimedia, Malnutrition, Vitamin A deficiency, Humanity, Vitamin, University, Human, Tropical disease, Dietary supplement

The study is designed to confirm that PFH-VAP's improved stability enables more vitamin A to be delivered into the human body after consumption.

Key Points: 
  • The study is designed to confirm that PFH-VAP's improved stability enables more vitamin A to be delivered into the human body after consumption.
  • Particles for Humanity has partnered with the University of Wisconsin-Madison and the Tropical Diseases Research Centre in Zambia to conduct the study as part of its effort to combat vitamin A deficiency (VAD).
  • VAD is a devastating public health problem affecting 190 million children and 19 million pregnant women worldwide.
  • Particles for Humanity transforms early-stage medical technology into products for people living in low and lower-middle income countries.

Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Retrieved on: 
Monday, October 9, 2023
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, ATTR, Symantec Endpoint Protection, Cardiomyopathy, Premedication, Food, IRR, OLE, Heart Failure Society of America, Shanda, Nyctalopia, TTR, Risk, Therapy, State, Amyloidosis, RNA interference, Vitamin A deficiency, Abdominal pain, Patisiran, Nausea, Headache, Polyneuropathy, Health status of Asian Americans, Paracetamol, Vitamin A, Periodic breathing, Month, CRL, ALN, ASM, Back pain, Patient, Bachelor of Medicine, Bachelor of Surgery, Medication, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RDA, Alnylam Pharmaceuticals, APOLLO, EAP, Serum, Quality of life, Pharmaceutical industry, Medical device, Medical imaging, Dietary supplement

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company’s supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company’s supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.
  • Patisiran is the established name for ONPATTRO®, which is approved by the FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.
  • The CRL did not identify any issues with respect to clinical safety, study conduct, drug quality or manufacturing.
  • As a result of the CRL, the Company will no longer pursue an expanded indication for patisiran in the U.S.

Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023

Retrieved on: 
Friday, October 6, 2023
Health, Other Health, Research, Science, Pharmaceutical, Cardiology, Biotechnology, ATTR, Cardiomyopathy, Premedication, Food, IRR, OLE, Heart Failure Society of America, Shanda, Nyctalopia, Risk, Therapy, Amyloidosis, Safety, RNA interference, Vitamin A deficiency, Abdominal pain, Patisiran, Nausea, Headache, FDA, Health status of Asian Americans, Polyneuropathy, Paracetamol, Vitamin A, Periodic breathing, ASM, Back pain, Patient, Medication, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RDA, APOLLO, PDUFA, EAP, Serum, Prescription Drug User Fee Act, Quality of life, Pharmaceutical industry, Dietary supplement

Data from an interim analysis of the ongoing open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of ATTR amyloidosis through 24 months will be presented.

Key Points: 
  • Data from an interim analysis of the ongoing open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of ATTR amyloidosis through 24 months will be presented.
  • Patisiran is the established name for ONPATTRO®, which is approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.
  • In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients.
  • Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Retrieved on: 
Wednesday, September 13, 2023
FDA, Health, Genetics, Pharmaceutical, Cardiology, Biotechnology, Prescription Drug User Fee Act, Nyctalopia, Therapy, Premedication, Serum, Advisory Committee, New Drug Application, Vitamin A deficiency, Vitamin A, IRR, Abdominal pain, Medication, Amyloidosis, Back pain, ATTR, Oncology Drug Advisory Committee, Patient, Risk, Paracetamol, Patisiran, Nausea, Periodic breathing, RNA interference, Cardiomyopathy, Polyneuropathy, Headache, RDA, Food, Pharmaceutical industry, Dietary supplement

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company’s common stock.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company’s common stock.
  • The U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee is meeting today to review the supplemental New Drug Application for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.
  • As previously announced, the FDA has set an action date of October 8, 2023 under the Prescription Drug User Fee Act.
  • Patisiran is the established name for ONPATTRO®, which is currently approved by the FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.

Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Retrieved on: 
Wednesday, September 13, 2023
Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Heart, Prescription Drug User Fee Act, Disease, Nyctalopia, Therapy, Heart failure, Parallel Walk Test, Premedication, Serum, Health status of Asian Americans, New Drug Application, Patisiran, Vitamin A deficiency, Quality of life, Vitamin A, IRR, Abdominal pain, Medication, Amyloidosis, APOLLO, TTR, Back pain, Shanda, Protein, ATTR, Patient, Physician, Risk, Paracetamol, Alnylam Pharmaceuticals, Nausea, Periodic breathing, RNA interference, Cardiomyopathy, Polyneuropathy, Headache, RDA, Food, Safety, Pharmaceutical industry, Medical device, Dietary supplement

The CRDAC voted 9:3 that the benefits of patisiran outweigh its risks for the treatment of the cardiomyopathy of ATTR amyloidosis.

Key Points: 
  • The CRDAC voted 9:3 that the benefits of patisiran outweigh its risks for the treatment of the cardiomyopathy of ATTR amyloidosis.
  • The CRDAC’s vote, while not binding, will be considered by the FDA when making its decision regarding the potential expanded indication for patisiran.
  • Patisiran is the established name for ONPATTRO®, which is approved by the FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.
  • Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).